JP2025016538A5 - - Google Patents

Download PDF

Info

Publication number
JP2025016538A5
JP2025016538A5 JP2024185456A JP2024185456A JP2025016538A5 JP 2025016538 A5 JP2025016538 A5 JP 2025016538A5 JP 2024185456 A JP2024185456 A JP 2024185456A JP 2024185456 A JP2024185456 A JP 2024185456A JP 2025016538 A5 JP2025016538 A5 JP 2025016538A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024185456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025016538A (ja
Filing date
Publication date
Priority claimed from CN202011325843.0A external-priority patent/CN114524878B9/zh
Application filed filed Critical
Publication of JP2025016538A publication Critical patent/JP2025016538A/ja
Publication of JP2025016538A5 publication Critical patent/JP2025016538A5/ja
Pending legal-status Critical Current

Links

JP2024185456A 2020-11-23 2024-10-21 二重特異性抗体及びその使用 Pending JP2025016538A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202011325843.0A CN114524878B9 (zh) 2020-11-23 2020-11-23 一种双特异性抗体及其用途
CN202011325843.0 2020-11-23
JP2023530940A JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用
PCT/CN2021/132195 WO2022105924A1 (zh) 2020-11-23 2021-11-22 一种双特异性抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023530940A Division JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2025016538A JP2025016538A (ja) 2025-02-04
JP2025016538A5 true JP2025016538A5 (cg-RX-API-DMAC7.html) 2025-06-05

Family

ID=81618526

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023530940A Active JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用
JP2024185456A Pending JP2025016538A (ja) 2020-11-23 2024-10-21 二重特異性抗体及びその使用
JP2024185455A Pending JP2025016537A (ja) 2020-11-23 2024-10-21 二重特異性抗体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023530940A Active JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185455A Pending JP2025016537A (ja) 2020-11-23 2024-10-21 二重特異性抗体及びその使用

Country Status (8)

Country Link
US (3) US20240002540A1 (cg-RX-API-DMAC7.html)
EP (3) EP4691565A3 (cg-RX-API-DMAC7.html)
JP (3) JP7846110B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230117160A (cg-RX-API-DMAC7.html)
CN (4) CN118878693A (cg-RX-API-DMAC7.html)
AU (2) AU2021383901C1 (cg-RX-API-DMAC7.html)
CA (1) CA3199721A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022105924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118878693A (zh) 2020-11-23 2024-11-01 康诺亚生物医药科技(成都)有限公司 一种双特异性抗体及其用途
CN114573702A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种新型肿瘤衔接器治疗药物的开发和应用
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种t细胞衔接器治疗剂的开发和应用
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
CN120712345A (zh) * 2022-12-30 2025-09-26 上药生物治疗(香港)有限公司 表达趋化因子受体的细胞及其用途
AU2024239034A1 (en) * 2023-03-18 2025-09-25 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-her3/muc1 antibodies and uses thereof
WO2026041029A1 (en) * 2024-08-21 2026-02-26 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Use of anti-her3/muc1 antibodies in cancer therapy
WO2026145542A1 (zh) * 2024-12-30 2026-07-09 康源博创生物科技(北京)有限公司 一种多肽以及包含其的抗体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2011124509A1 (de) 2010-03-30 2011-10-13 Behr Gmbh & Co. Kg Temperierelement und temperiervorrichtung für ein fahrzeug
WO2012023053A2 (en) * 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
AU2015292744C1 (en) * 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3778640A1 (en) 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3305322A4 (en) 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
CN108602889A (zh) 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
CN111201031B (zh) * 2017-08-25 2024-11-01 诺夫免疫股份有限公司 抗CD47 x抗间皮素抗体及其使用方法
WO2019244973A1 (ja) * 2018-06-20 2019-12-26 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
EP3674316A1 (en) * 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
CN111454357B (zh) 2019-08-14 2022-03-15 康诺亚生物医药科技(成都)有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN112062855B (zh) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
CN118878693A (zh) 2020-11-23 2024-11-01 康诺亚生物医药科技(成都)有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种t细胞衔接器治疗剂的开发和应用
CN114573702A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种新型肿瘤衔接器治疗药物的开发和应用

Similar Documents

Publication Publication Date Title
JP2022191383A5 (cg-RX-API-DMAC7.html)
JP2024109678A5 (cg-RX-API-DMAC7.html)
JP2024534545A5 (cg-RX-API-DMAC7.html)
JP2023516195A5 (cg-RX-API-DMAC7.html)
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2023526774A5 (cg-RX-API-DMAC7.html)
JP2021507698A5 (cg-RX-API-DMAC7.html)
JP2023506750A5 (cg-RX-API-DMAC7.html)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2021533159A5 (cg-RX-API-DMAC7.html)
JP2019501883A5 (cg-RX-API-DMAC7.html)
JP2017537896A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2017534646A5 (cg-RX-API-DMAC7.html)
JP2025501775A5 (cg-RX-API-DMAC7.html)
JP2024024114A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2021534797A5 (cg-RX-API-DMAC7.html)
JP2017534644A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2025067915A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
RU2019134462A (ru) Антитела, связывающиеся с steap-1
CN110869390A (zh) 抗pd-l1抗体及其用途